Goldman Sachs Group Inc Cytek Biosciences, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,022,744 shares of CTKB stock, worth $6.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,022,744
Previous 1,357,251
24.65%
Holding current value
$6.7 Million
Previous $7.57 Million
25.18%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CTKB
# of Institutions
134Shares Held
71.7MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$112 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$77.1 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$62.2 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$43.6 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$27.3 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $882M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...